Top Markets
#1 Helium Helium +58.78%
#2 Seeker Seeker +45.10%
#3 Pons Pons +37.43%
#4 Tensor Tensor +27.31%
#5 UnifAI Network UnifAI Network +26.57%
#6 TENDIES TENDIES +21.30%
#7 DAPPOS DAPPOS +17.14%
#8 Zylo Ecosystem Zylo Ecosystem +16.61%
#9 Bounce Bounce +16.46%
#10 LAB LAB +16.14%
Coin of the day
Helium Helium
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rang în acțiuni #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Preț acțiune
$9.50
Ultima sincronizare: 2025-01-08
Capitalizare de piață
$819.52M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Poseida Therapeutics, Inc. (PSTX)

Categorie

Healthcare
Raport P/S pentru Poseida Therapeutics, Inc. (PSTX)
Raport P/S la data de August 2026 TTM: 14.31
Conform celor mai recente rapoarte financiare și prețului acțiunilor Poseida Therapeutics, Inc., raportul P/S actual (TTM) este 14.31. La sfârșitul anului 2022, compania avea un P/S de 2.92.
Istoricul raportului P/S pentru Poseida Therapeutics, Inc. din 2016 până în 2026
Raport P/S la sfârșitul fiecărui an
An Raport P/S Schimbă
2026 (TTM) 14.31 205.78%
2023 4.68 60.18%
2022 2.92 -99.98%
2021 13.55K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 204.33 119.21%
2016 93.21 0.00%
Raport P/S pentru companii similare sau competitoare
Companie Raport P/S Diferență raport P/S Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -28.95%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -29.22%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -79.37%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -21.20%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH